Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Signatera Is Submitted to Japan's PMDA for Companion Diagnostic Approval in MIBC

5 August 2026 · By · Wire by Fusion42

Published

5 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

Japan

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

Signatera, a companion diagnostic test, has been submitted to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval to detect minimal residual disease in muscle-invasive bladder cancer (MIBC). This submission marks a key regulatory step for integrating Signatera into clinical use in Japan.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Japanese approval processes are opening for new companion diagnostics in bladder cancer. You should prepare to engage Japanese clinical and regulatory partners to capitalise on market access opportunities.

◆ Coverage

1 source · 5 Aug 2026

◆ Related on Wire

◆ Topics

Medtechregulatory-approvalmedtechcompanion-diagnosticsjapan-marketoncology